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[57] ABSTRACT 
Anticonvulsant compositions comprise as the active 
ingredient a compound selected from the group consist 
ing of those of the formulae: 
wherein R1 is phenyl, 4-pyridy1, 3-pyridyl, o_r Z-pyridyl, 
and R2 is hydrogen, m- or p-methyl, p-methoxy, m- or 
p-chloro, m- or p-bromo, m- or p-?uoro, m- or p-tri 
?uoromethyl, 3,4-dich1oro or 3,5-dichloro. The compo 
sitions are administered to mammals in an amount to 
provide a dosage amount ranging from about 25 rug/kg 
to 300 mg/kg. 
35 Claims, N0 Drawings 
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1,2,3-TRIAZOLE ANTICONVULSANT DRUGS 
TECHNICAL FIELD 
This invention relates to lH-l,2,3-triazoles and their 
use as a novel class of anticonvulsant drugs, and more 
particularly relates to certain additional new 1H-l,2,3 
triazoles, their methods of preparation, and composi 
tions for their use in the treatment of convulsive disor 
ders. 
BACKGROUND ART 
Studies over the past 15 years suggest that the pre 
vailing rate of epilepsy in the United States is between 5 
and 20 per 1000, and recent estimates drawn from popu 
lation surveys indicate that the higher rates are closer to 
the true prevalence. This means that 1 to 4 million 
Americans suffer from some form of epilepsy. For cer 
tain types of seizures there are no speci?c drugs avail 
able; for seizures that are controlled with currently 
available therapy, a new drug may allow a reduction in 
the toxic side effects. Despite these facts, between 1960 
and 1974, no new anticonvulsant drug was marketed in 
the United States (with the exception of diazepam, 
which was marketed primarily as a minor tranquilizer) 
(Vida, J. A. “Anticonvulsants,” Academic Press, New 
York, 1977). However, since the approval of carbamaz 
epine in 1974 and clonazepam in 1975, and sodium di 
propylacetate, eterobarb, mexiletine and others in 
1977-1978, there has been a resurgence of interest in the 
development of better anticonvulsant drugs for the 
management of epilepsy. Also responsible for this re 
newed interest is the establishment of the Anticonvul 
sant Screening Project of the Antiepileptic Drug De 
velopment (ADD) Program of NINCDS (National 
Institute of Neurological and Communicative Disorders 
and Stroke) of NIH, in January, 1975. 
In recent years hundreds of different heterocyclic 
compounds have been synthesized and screened for 
anticonvulsant activity. These include mostly ?ve and 
six membered ring systems containing up to three or 
four heteroatorns and seven membered ring systems 
related to the diazepines. Among the nitrogen contain 
ing heterocycles, a considerable amount of work has 
been done in the areas of ?ve membered rings bearing 
one or two nitrogen atoms. 
Five membered rings with 3 or 4 nitrogen atoms that 
have been investigated, include mostly, 1,2,4-triazo1es 
and some tetrazoles. Very little has been done on 1H 
1,2,3-triazoles (Popp, F. D., In “Anticonvulsants,” J. A. 
Vida, Ed. Academic Press, New York, 1977). 
The literature indicates that to date there are only 
two references relating to studies on the anticonvulsant 
potential of lH-1,2,3-triazoles. Unlike the simple 1-5~ 
substituted-1,2,3-triazoles of this invention, both these 
references are to fused ring benzotriazoles of the struc 
tures I and II shown below by Gilbert and Rumanowski 
(Gilbert, E. E., 
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and Rumanowski, E. 1., US. Pat. No. 3,592,822, 1971) 
and structure III by Wolf (Wolf, M., US. Pat. No. 
3,394,143, 1968). In addition certain substituted 1H 
l,2,3-triazoles IV and V have been shown to afford 
some degree of protection against oxotremorin induced 
tremors in mice at 100 mg/kg. (Miller, A. D., 
[- N-R R2 | 
N / N / R1 
(IV) (V) 
I CI, United States, Ger. Pat. No. 2,648,826 (Cl. 
CO7D249/O4), 05 May, 1977; US. application No. 
626,140, 26th Oct., 1975, 53 pages) and (ICI Americas, 
Inc., Belg. 853,978 (Cl. CO7D), 26th Oct. 1977, Appl. 
26th Apr. 1977, 11 pages). Compounds of the type IV 
and V have been investigated as potential tranquilizers 
or antianxiety agents but not as anticonvulsants. 
The 1,2,3-triazoles are a novel group of anticonvul~ 
sant compounds because their heterocyclic ring system 
is different from that of conventional anticonvulsant 
drugs. The presently marketed antiepileptic drugs, for 
the major part, have a dicarboximide function and/or a 
disubstituted quaternary carbon group (barbiturates, 
hydantoins, succinimides, oxazolidinediones) or closely 
related structure (pyrimidone). On the other hand, the 
dicarboximide function, which contributes to the inher 
ent hypnotic and sedative activity of the barbiturates 
and related compounds, is absent in the triazoles. 
The chemistry of 1,2,3-triazoles has been extensively 
studied (Gilchrist, T. L., and Gymer, G. E., “Advances 
in Heterocyclic Chemistry” Vol. 16, 1974, pp. 33485; 
Benson, F. R., and Savell, W. L., Chemical Reviews, 
46, 1, 1950; Boyer, J. H., in “Heterocyclic Com 
pounds”, Edited by R. C. Elderfield, Vol. 1, p. 384-461, 
Wiley, New York, 1961), which also include the appli 
cant’s own publications on the synthesis of l-aryl-S 
heteroaryl-substituted lH-l,2,3-triazoles. However, 
with the exception of the few 1,2,3-triazoles mentioned 
earlier, no studies have been conducted on 1,2,3 
triazoles for use as anticonvulsants. 
As indicated, the present applicant has published two 
papers involving her work on triazoles. The publica 
tions discuss primarily a convenient general synthetic 
route for the preparation of 1,5-substituted 1,2,3 
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triazoles by permanganate oxidation of the respective 
triazolines. (Kadaba, P. K. “Synthesis, International 
Journal of Methods in Synthetic Organic Chemistry,” 
No. 9: September, 1978, pp. 694-695). (Kadaba, P. K., 
“Journal fur praktische Chemie,” Vol. 324, 1982, pp. 
857-864.) 
In both these publications, however, there is no dis 
closure of the use of any of the 1,2,3-triazole com 
pounds as anticonvulsants. 
SUMMARY OF THE INVENTION 
It is accordingly one object of the present invention 
to provide certain triazoles as anticonvulsant drugs. 
A further object of the present invention is to provide 
several new lH-l,2,3-triazoles and methods for their use 
in the treatment of convulsive disorders. 
A still further object of the present invention is to 
provide anticonvulsant compositions containing as the 
essential ingredient certain lH-l,2,3-triazoles and use of 
these triazoles as antiepileptic drugs in the treatment of 
convulsive disorders such as epilepsy. 
Other objects and advantages of the present invention 
will become apparent as the description thereof pro 
ceeds. 
In satisfaction of the foregoing objects and advan 
tages, there is provided by this invention anticonvulsant 
compositions comprising as the active ingredient, a 
compound selected from those of the following formu 
lae: 
N 
wherein R1 is phenyl, 4-pyridyl, 3-pyridyl, or Z-pyridyl, 
and R2 is hydrogen, m- or p-methyl, p-methoxy, m- or 
p-fluoro, m- or p-chloro, m- or p-bromo, m- or p-tri 
fluoromethyl, 3,4-dichloro, or 3,5-dichloro substituent. 
Also provided are methods for administration of the 
anticonvulsant compositions of this invention to mam 
mals in the treatment of convulsive disorders such as 
epilepsy including petit mal and grand mal. 
There is also provided by this invention certain new 
compounds which are useful as anticonvulsant drugs. 
These compounds may be characterized by the follow 
ing general formulae: 
wherein R1 is 4-pyridyl, or 3-pyridyl, and R2 is m 
methyl, m- or p-?uoro, m- or p-chloro, m- or p-bromo, 
m- or p-trifluoromethyl, 3,4-dichlor0, or 3,5-dichloro. 
DESCRIPTION OF PREFERRED 
EMBODIMENTS 
As indicated above, this invention relates to certain 
1,2,3-triazoles which are useful as anticonvulsants. The 
triazoles of this invention are to be named as lH-1,2,3 
triazoles. The triazoles of this invention are substituted 
in the l and 5 positions by aryl or heterocyclic groups 
which may also contain substituents. The triazole com 
pounds of this invention have potent to moderate anti 
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convulsant activity as antiepileptic drugs in the treat 
ment of convulsive disorders such as petit mal (absence 
seizures) and grand mal (major motor seizures). 
In one aspect of the invention, it relates to novel 
anticonvulsant compositions which comprise as the 
active ingredient a compound selected from those of the 
following formulae: 
wherein R1 is phenyl, 4-pyridyl, 3-pyridyl, or 2-pyridyl, 
and R2 is hydrogen, m- or p-methyl, p-methoxy, m- or 
p-fluoro, m- or p-chloro, m- or p-bromo, m- or p-tri 
fluoro methyl, 3,4-dichloro or 3,5, dichloro substituents. 
In a further aspect of the present invention, new com 
pounds are provided which have anticonvulsant activ 
ity and which are of the following general formulae: 
R] N 
H | 
éN N 
In the above formulae, R1 is 3-pyridyl, or 4-pyridyl, 
and R2 is m-methyl, m- or p-fluoro, m- or p-bromo, m 
or p-chloro, m- or p-tri?uoromethyl, 3,4-dichloro, or 
3,5-dichloro substituent. 
There is further provided by this invention methods 
for administration of the anticonvulsant composition to 
mammals including animals and humans. 
The triazoles of this invention may be prepared by 
the oxidation of 4,5-dihydro-lI-I-1,2,3-triazoles (A2 
l,2,3-triazolines), which in turn, are prepared by the 
reaction of diazomethane with Schiff bases as described, 
for example, by Mustafa, A., (J. Chem. Soc.), 234 
(1949), and by Buckley, G. D., (J. Chem. Soc), 1850, 
(1954). Further methods of preparation of 1,2,3-triazo 
lines involving 1,3-dipolar cycloaddition reactions are 
described in the applicant’s own publications in Kadaba, 
et al. (J. Org. Chem. 26, 2331 (1961), by Kadaba in 
“Tetrahedron,” 22, 2453 (1966), by Kadaba in “Tetrahe 
dron,” 25, 3053 (1969) and J. Heterocyclic Chem, 12, 
143, (1975). This reaction proceeds generally in accor 
dance with the following equation. (Eq. 1) 
(Eq- 1) 
Dioxane + H2O 
+ CHZNZ Room temperature 5 
R2 
111T- N l / N / 
A2-l,2,3-Triazolines 
In the above equation R1 and R2 are as de?ned above. 
Kinetic studies on solvent effects of this reaction 
indicate that protic solvents such as water have a gen 
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eral accelerating effect on the reaction and by carrying 
out the addition reaction in an aqueous dioxane solution, 
high yields of triazolines are produced. 
The 1,2,3-triazolines undergo smooth oxidation to 
1,2,3-triazoles, using potassium permanganate in a two 
phase system (benzene-water or chloroform-water), in 
the presence of a phase-transfer catalyst such as tet 
rabutylammonium chloride (Kadaba, P. K., Synthesis, 
694, 1978 and Kadaba, P. K., J. prakt. Chem., 324, 857, 
1982) in accordance with the following equation. 
(Equation 2) 
NBu4Cl (Catalyst) 
Benzene-water E 
The permanganate oxidation of triazolines to tria 
zoles provides a general method for the synthesis of 
both 1,5-diaryl and l-aryl-5-heteroaryl substituted 1H 
l,2,3-triazoles. The reaction is superior to triazole syn 
thesis by azide addition to acetylenes. The lack of reac 
tivity of acetylenes as well as the formation of isomeric 
1,4- and 1,5-substituted triazoles in the cycloaddition of 
phenyl azide to aryl acetylenes limit the utility of the 
acetylene-azide addition reaction in triazole synthesis. 
(Gilchrist, T. L., and Gymer, G. E., Adv. Heterocycl. 
Chem., 16, 33, 1974; Stephan, E., Bull Soc. Chim., Fr., 
7-8, 364, 1978; L’abbe, G. and Hassner, A., Bull. Soc. 
Chim Belg. 80, 209, 1971; Alonso, G., Garcia-Lopez, M. 
T., Garcia-Munoz, G., Madronero, R., and Rico, M., J. 
Heteracycl. Chem, 7, 1269, 1970). 
As pointed out, the triazole compounds and resulting 
anticonvulsant compositions of this invention are useful 
in the treatment of convulsive disorders. The potency 
of the compounds range from those which are very 
potent to those of moderate potency. A series of tria 
zoles of this invention has been evaluated in Phase I 
anticonvulsant screening using two seizure models in 
the mouse, the maximal electro-shock seizure (MES) 
test and the subcutaneous pentylenetetrazole (Met 
razole) seizure threshold (scMet) test. These two meth 
ods of seizure provocation elicit reliably well character 
ized seizure phenomena (Chen. G., et al. Proc. Soc. 
Exp. Biol. Med., 87, 334 (1954), and together have been 
shown suf?cient to identify all compounds known to 
demonstrate anticonvulsant activity in other tests. 
Based on the Phase I screening results, the compound 
tested is placed in one of three categories. Those failing 
to demonstrate anticonvulsant activity at doses up to 
300 mg/kg are considered inactive. Class II compounds 
show anticonvulsant activity at doses greater than 100 
mg/kg or show activity at 100 mg/kg which is not 
reinforced by similar activity at 300 mg/kg. Thus com 
pounds of Class or Group II demonstrate anticonvul 
sant activity without signs of neurological de?cit, but 
do not have signi?cant potency. The Class I compounds 
are those which are most promising as anticonvulsants. 
They demonstrate anticonvulsant activity in either the 
MES test or the scMet test, or both at doses of 100 
mg/kg or 30 mg/kg without signs of neurological de? 
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cit and thus have an estimated protective index of 
greater than 1. 
The following table presents the results of these tests 
with respect to certain compounds of the present inven 
tion. This Table l identi?es the speci?c compounds 
tested by chemical name, and provides the anticonvul 
sant activity based on classi?cation in Group I or Group 
11. 
TABLE I 
Anticonvulsant Activity 
Compound Group Classi?cation 
l. l-(p-Chlorophenyl)- I 
5-phenyl-lH—l,2,3-triazole 
2. l-(p-Bromophenyl)- I 
As shown in the above table, the most potent com 
pounds are compounds 1,2,3,7,9,10,l1,12 and 14. These 
compounds belong to Class I and with the exception of 
compounds 7 and 9, the remaining seven compounds do 
not exhibit signi?cant signs of neurological de?cit at 
their effective dose levels. In addition, compounds 8 
and 13 in Class II are also effective anticonvulsant com 
pounds because they give 100% protection at 300 
mg/kg, without any signs of neurological de?cit. Thus, 
these nine compounds, l,2,3,8,l0,1 1,12,13 and 14, repre 
sent the preferred embodiments of the anticonvulsant 
compositions of this invention. Compound 10 which is 
1-(para-chlorophenyl)-5-(3-pyridyl)-lH-l,2,3-triazo1e 
and Compound 11 which is 1-(p-bromophenyl)-5-(3 
pyridyl)-lH-l,2,3-triazole are the most preferred com 
pounds of this invention. 
As indicated above, although other preparative reac 
tions could be used for the triazoles of this invention, 
the permanganate oxidation of 1,2,3-triazolines in a 
phase-transfer catalyzed reaction is the method of 
choice for the synthesis of 1,5-substituted triazoles, 
especially l-aryl-S-heteroaryl-lH-1,2,3-triazoles (Equa 
tion 2). Several l-aryl-S-heteroaryl-1,2,3-triazoles were 
4,610,994 
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prepared for the ?rst time by this method (P. K. 
Kadaba, Synthesis, 694, 1978). 
A mixture of 1,2,3-triazoline (0.005 mol) in benzene 
(75 ml), potassium permanganate (0.025 mol) in water 
(100 ml) and tetrabutylammonium chloride (0.5 mmol) 
was heated under re?ux with magnetic stirring for 4 
hours or more. The reaction mixture was then cooled to 
room temperature, treated with sodium sul?te to de 
stroy excess potassium permanganate and ?ltered under 
suction to remove the manganese dioxide. The residue 
was washed twice with hot benzene and combined with 
benzene extracts of the ?ltrate, washed with water, 
dried, and evaporated under reduced pressure. An oily 
residue was obtained, which upon cooling and tritura 
tion with diethylether, yielded the triazole as a crystal 
line solid. Recrystallization from diethyl ether or a mix 
ture of petroleum ether and acetone or methanol 
yielded the analytically pure products. Chloroform can 
easily be used in place of benzene in certain reactions. 
Furthermore, since Schiff bases (imines) bearing a 
range of aromatic or heterocyclic substituents can be 
readily prepared, the CHgNg-imine reaction is particu 
larly suited for the synthesis of the various 1,5-sub 
stituted triazolines required for the oxidation reaction. 
The addition of diazomethane to imines occurs regiose 
lectively and thus there is no problem of isomeric tri 
azole formation as in azide-acetylene addition reactions. 
As pointed out above, this addition is preferably carried 
out in aqueous dioxane solutions according to the appli 
cant’s previous publications. In a typical preparation, 
the Schiff base is dissolved in a cold, freshly prepared 
solution of CHZNZ in wet dioxane. The reaction mixture 
is then allowed to stand at 15°-20° C. for 2—4 days in the 
case of the reactive anils and 6-7 days in the case of the 
slow reactions. At the end of this period, the mixture is 
cooled and diluted with water to precipitate the triazo 
line adduct. 
The CHZNZ for the reaction is prepared conveniently 
from N,N'-nitrosomethylurea in the same manner that 
1~ undistilled ethereal solutions are obtained, but using 
1,4-dioxane in place of diethyl ether. Dioxane is the 
solvent of choice because of its easy miscibility with 
water and the ease with which it can be substituted for 
diethyl ether. The CHZNZ solution thus obtained con 
tains water in suf?cient amounts to catalyze the reaction 
and is used immediately. 
The'Schiff bases are prepared using standard proce 
dures by heating a mixture of the appropriate adehyde 
and amine in ethanol or alternatively by heating the 
mixture in benzene followed by azeotropic removal of 
the water, the latter being a more suitable procedure in 
dif?cult cases. _ 
The anticonvulsant compounds of the present inven 
tion may be administered to animals or humans at doses 
ranging from about 25 mg/kg up to about 300 mg/ kg. 
Preferred levels of administration range from about 25 
mg/kg up to 100 mg/kg. The active ingredients or 
compounds of this invention may be administered in 
any desired form by injection or in the oral form. Con 
ventional adjuvents and carriers may be employed in 
combination with about 0.001 to 2.0 wt.% of the active 
ingredient. Thus the anticonvulsant compositions of this 
invention may be administered in pill form or by injec 
tion. As indicated above, the dosage rate ranges from 
about 25 mg/kg up to about 300 mg/kg. 
The following examples are presented to illustrate the 
invention but it is not to be considered as limited 
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thereto. In the examples and throughout the speci?ca 
tion, parts are by weight unless otherwise indicated. 
EXAMPLE 1 
Using the reaction of Equation 2 described above 
involving potassium permanganate oxidation of 1,2,3 
triazolines, the following compounds were prepared. In 
the following Table 2, melting points and yields are 
given for new compounds prepared. 
TABLE 2 
M. Compound Pt. °C. Yield % 
109-1005 
139-140 60 
130-131 
120-122 70 
136-139 70 
155-1565 80 
160-162 74 
87-89 
125-1265 
76-79 47 
115-116 47 
122-1215 66 
These compounds were identi?ed through their ele 
mental analyses, characteristic melting point (unlike 
1,2,3-triazolines, 1,2,3-triazoles do not decompose at 
their melting point with vigorous evolution of nitro 
gen), and NMR spectra, which exhibit a sharp singlet 
signal in the 88.0 region characteristic of the 4-CH 
proton in the l,5-substituted-1,2,3-triazoles. The CH 
signal for the 1,4-substituted triazoles would appear at 
8<8 (Stephan, E., Bull. Soc. Chim. FL, 7-8 364, 1978). 
These compounds were then evaluated in accordance 
with the methods set forth above for anticonvulsant 
characteristics. The results are set forth in Table 1 
above. As pointed out with respect to Table l, the com 
pounds demonstrate anticonvulsant activity in either 
the MES test or the scMet test or both. Compounds of 
Class I demonstrate this activity at doses of 100 mg/kg 
or 25 mg/kg without signs of neurological de?cit and 
thus have an estimated protective index of greater than 
1. 
EXAMPLE 2 
One of the compounds, Compound 10, which is 1 
(parachlorophenyl)-5-(3-pyridyl)- lH-1,2,3-triazole, was 
evaluated in further studies to provide additional infor 
4,610,994 
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mation as to its general pro?le of anticonvulsant activ 
ity. 
Thirty minutes after administration, Compound 10 of 
this invention exhibited anti-maximal electroshock 
(MES) at 30 mg/kg and anti-Metrazol (sc Met) activity 
at 300 mg/kg. Rotorod toxicity was seen in all four 
animals given 300 mg/kg of the test substance. Four 
hours after administration, the candidate substance was 
effective by the MES and scMet tests at 300 mg/kg; one 
of two animals was also toxic at this dose level. Thus, 
the pro?le of anticonvulsant activity of Compound 10 
was characterized by the ability to modify maximal 
electroshock seizure pattern and to elevate the Metrazol 
seizure threshold in nontoxic doses. Accordingly, the 
test substance (Compound 10) was subjected to Phase II 
Anticonvulsant Quanti?cation in Mice i.p., Phase III 
Toxicity Pro?le in Mice i.p., Phase IV Anticonvulsant 
Quanti?cation in Mice p.o., Phase V Antiepileptic Drug 
Differentiation in Mice i.p., Phase VI Anticonvulsant 
Quanti?cation in Rats p.o., and Phase VII Chronic 
Administration in Rats p.o. (tolerance, hexobarbital, 
and liver microsomal enzyme studies). The results ob 
tained provided the basis to compare the anticonvulsant 
activity and toxicity of Compound 10 with those of 
clinically useful antiepileptic drugs. 
In these experiments, male albino mice (CF No. 1 
strain; 18 to 25 g wt) obtained from Charles Rivers, 
Wilmington, Mass, and male albino rats (Sprague Daw 
ley, 100 to 150 g wt) obtained from Simonsen, Gilroy, 
Ca1., were used as experimental animals. All animals 
were allowed free access to both food (S/L Custom 
Lab Diet-7) and water, except when they were re 
moved from their cages for the experimental procedure. 
Compound 10 was compared with four prototype 
antiepileptic agents (phenytoin, phenobarbital, ethosux 
imide, and valproate). Compound 10 was administered 
in the requisite volume of 30% polyethylene glycol 400, 
whereas phenytoin, phenobarbitol, ethosuximide, and 
valproate were administered in 0.9% sodium chloride 
solution. The drugs were administered either orally or 
intraperitoneally in a volume of 0.01 ml/ g body weight 
in mice and 0.04 ml/lO g in rats. All tests were con 
ducted at the previously determined time of peak drug 
effect. To determine anticonvulsant potency and toxic 
ity, groups of at least eight mice or rats were tested with 
various doses of the drug until at least four points were 
established between the limits of 100% protection or 
toxicity and 0% protection or toxicity. The dose of drug 
required to produce the desired endpoint in 50% of 
animals (EDSO) in each test, the dose eliciting evidence 
of minimal neurological toxicity in 50% of animals 
(TD50), the 95% con?dence interval, the slope of the 
‘regression line, and the standard error (S.E.) of the 
slope were then calculated by means of a computer 
program written by NINCDS. 
The pro?le of anticonvulsant activity for each sub 
stance was established by ?ve tests: one electrical and 
four chemical. The electrical test employed was the 
maximal electroshock seizure pattern test. This test 
measures the ability of the test drug to abolish the hind 
limb tonic-extensor component of maximal electro 
shock seizures (mice, 50 mA; rats, 150 mA; 60 Hz, cor 
neal electrodes, 0.2 sec stimulus duration); this amount 
of current is approximately six times the threshold and 
reveals the ability of the test substance to prevent sei 
zure spread. The four chemical tests include the subcu 
taneous Metrazol Seizure Threshold Test (sc Met Test), 
subcutaneous Bicuculline Seizure Threshold Test (sc 
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Bic Test), subcutaneous Picrotoxin Seizure Threshold 
Test (sc Pic Test), and the subcutaneous Strychnine 
Seizure Pattern Test (sc Strych Test). Except for the sc 
Strych Test, these tests measure the ability of anticon 
vulsants to afford complete protection against threshold 
seizures induced by the subcutaneous injection of the 
CD97 of the convulsant agent. The so Strych Test mea 
sures the ability of the test substance to abolish all tonic 
components of seizures induced by the subcutaneous 
injection of the CD97 of strychnine. The sc CD97 of 
Metrazol, bicuculline, picrotoxin, and strychnine in 
mice is 85, 2.70, 3.15, and 1.20 mg/kg, respectively; the 
sc CD97 for Metrazol in rats is 70 mg/kg. 
The pro?le of toxicity for each test drug was estab 
lished by the following procedures: Firstly, the minimal 
neurotoxic dose (TD50) was determined by the rotorod 
procedure at the time of peak neurotoxic effect. When a 
normal mouse is placed on a knurled rod one inch in 
diameter rotating at a speed of six rpm it can maintain its 
equilibrium for long periods of time. Neurological de? 
cit is indicated by inability of the mouse to maintain its 
equilibrium for one minute in each of three trials on this 
rotating rod. Neurological de?cit in rats is indicated by 
ataxia, loss of placing response and muscle tone. Se 
condly, the overt signs and symptoms of toxicity in 
duced by each prototype agent and test substance were 
determined by giving two mice either lTD50, 2TD50’s, 
or 4TD50’s and observing and testing them 10, 20, and 
30 minutes and l, 2, 4, 6, 8, and 24 hours after drug 
administration for the onset, intensity, and type of overt 
toxicity. These observations also provide preliminary 
information essential for the subsequent determination 
of the HD50 and LD50. The HDSO represents the me 
dian dose at which 50% of animals lose their righting 
re?ex. The 24-hour LD50 represents the median dose 
which causes death in 50% of the animals within 24 
hours. 
Except for bicuculline, all convulsant drugs (Metra 
zol, picrotoxin, and strychnine) administered to mice 
were dissolved in suf?cient 0.9% sodium chloride solu 
tion to make a concentration of 0.85%, 0.032%, and 
0.012%, respectively. Bicuculline was dissolved in 1 ml 
of warmed 0.1N HCl with the aid of a micro-mixer and 
suf?cient 0.9% sodium chloride added to make a 
0.027% solution; the solution was used 15 to 45 minutes 
after preparation. Metrazol (3.5%) was administered to 
rats in a solution of 0.9% sodium chloride. 
All convulsants were administered subcutaneously 
into a loose fold of skin on the back of the neck in a 
volume of 0.01 ml/ g body weight in mice; Metrazol was 
injected in a volume of 0.02 ml/l0 g body weight in 
rats. The convulsant drugs were administered at the 
previously determined time of peak anticonvulsant ac 
tion of the drug under study. Except for picrotoxin 
treated animals, the mice (eight animals/group) were 
then observed for at least 30 minutes for the presence or 
absence of a seizure. The animals treated with picro 
toxin were observed for periods of 45 to 60 minutes for 
the presence or absence of a seizure. Except for strych 
nine, absence of a ?ve-second episode of clonic spasms 
(threshold seizure) was taken as protection. In the case 
of strychnine, complete abolition of the hindleg tonic 
extension was taken as protection. 
The results obtained in Phase II Anticonvulsant 
Quanti?cation Studies in Mice i.p., are shown in Table 
3. It may be seen from the table that the times of peak 
effect (TPE) of the ?ve compounds range from 15 min 
utes to two hours. The TPE of Compound 10 was 60 
4,610,994 
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minutes for the rotorod toxicity test and 30 minutes for 
the anticonvulsant tests. 
With respect to anticonvulsant activity, phenobarbi 
tal, Compound 10 of this invention and valproate had 
signi?cant anticonvulsant activity in nontoxic doses as 
measured vby both the maximal electroshock seizure 
(MES: EDSO’s: 21.78, 65.76, and 271.66 mg/kg. respec 
tively) and subcutaneous Metrazol seizure (scMet; 
EDSO’s: 13.17, 26.95, and 148.59 mg/kg, respectively) 
tests. In contrast to the above, phenytoin had signi?cant 1O 
anti-MES activity (EDSO: 9.50 mg/kg) but did not pro 
tect against subcutaneous Metrazol seizures. Ethosuxi 
mide, on the other hand, was not able to protect mice 
from maximal electroshock seizures but exhibited signif 
icant anti-Metrazol activity in nontoxic doses (EDSO: 
130.35 rug/kg). 
With regard to minimal neurotoxicity, ethosuximide 
and valproate were the least toxic (TDSO’s: 440.83 and 
425.84 mg/kg, respectively), whereas phenytoin and 
phenobarbital were the most toxic with TD50’s of 65.46 20 
and 69.01 mg/kg, respectively. The Compound 10 of 
this invention was intermediate in toxicity with a TD50 
of 244.51 mg/kg. 
TABLE 3 
5 
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by the sc Met test with P.I.’s of 3.38, 2.87, and 5.24, 
respectively. 
Phase III, Toxicity Pro?le Studies in Mice given 
lTDSO, 2TD50’s and 4TD50’s of Compound 10 intra 
peritoneally, were also carried out on the compounds. 
The toxicity pro?le induced by 1TD50 of Compound 
10 was characterized by decreased motor activity, roto 
rod toxicity, ataxia, and decreased respiration. In addi 
tion to these symptoms, animals given 2T50’s of Com 
pound 10 exhibited cyanosis, muscle relaxation, and loss 
of righting re?ex. Both mice given 4TD50’s of Com 
pound 10 of this invention displayed all the symptoms 
characteristic of those given 1TD5O and 2TD50’s of the 
test drug; however, the symptoms were more intense. 
Animals given 1TD50 were normal after 24 hours, 
whereas both mice given 2TD50’s were dead after 24 
hours; one animal given 4TD50’s was dead 4 hours after 
drug administration and the other was dead at 24 hours. 
A more detailed qualitative description of the pro?le of 
acute toxocity in mice (i.p.) of Compound 10 as well as 
phenytoin, phenobarbital, ethosuximide, and valproate 
is shown in Table 4. In addition, the hypnotic dose 50 
(HDSO) and lethal dose 50 (LD50) of these compounds 
PROFILE OF ANTICONVULSANT ACTIVITY OF 
INTRAPERITONEALLY ADMINISTERED COMPOUND 10 
AND SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE. 
Time Rotorod 
ADD No. of Test TD50 ED50 (mg/kg) and PI 
Substance (hrs) (mg/kg) MES sc MET 
Compound 10 1, 1, 1 244.51 65.76 26.95 IE] 
(22182-27517) (51.82-83.19) 6.89-55.08) 
[13.86] [5.43] [1.21] 
Phenytoin 2, 2, 2 65.46 9.50 [E] No Protection @Zl 
(52.49-72.11) (23.13-10.44) up to 300 
[15.23] [13.66] 
Phenobarbital 4}, 1, 1 69.01 21.78 13.17 
(62.84-72.89) (14.99-25.52) (5.87-15.93) 
[24.67] [14.92] [5.93] 
Ethosuximide %, Q, § 440.83 No protection @ 130.35 
(38309-48534) up to 1000 (11099-15045) 
[18.37] [10.06] 
valproate 1, I, .1, 425.84 271.66 148.59 
(36891-45040) (24697-33789) (12264-17702) 
[20.34] [12.83] [11.84] 
( ) 95% Con?dence interval 
[ ] Slope, regression line 
" Protective Index (P.l.) = TDSO/EDSO 
It may also be seen from Table 3 that the protective 60 
indices (TD50/ED50=P.I.) by the MES test range 
from <O.44 for ethosuximide to 6.89 for phenytoin. The 
P.I.’s of the remaining three compounds (valproate, 
Compound 10 of this invention and phenobarbital) are 
1.57, 3.72, and 3.17, respectively. The P.I.’s of com 
pounds by the sc Met test range from <O.22 for phenyt 
oin to 9.07 for the compound of this invention. Ethosux 
imide, valproate, and phenobarbital were also effective 
65 
are also listed. As shown in the table, the HDSO and 
LD50 of Compound 10 were not signi?cantly different 
(525.97 and 569.26 mg/kg, respectively). The HDSO for 
Compound 10 was signi?cantly higher than that for 
either phenobarbital (135.45 mg/kg) or phenytoin 
(178.34 mg/kg), but signi?cantly lower than that for 
either valproate (885.53 mg/kg) or ethosuximide 
(850.61 mg/kg). 
13 
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PROFILE OF ACUTE NEUROTOXICXTY 
OF INTRAPERITONEALLY ADMINISTERED COMPOUND 10 AND SOME PROTOTYPE 
ANTIEPILEPTIC DRUGS IN MICE 
ADD No. m 
or Pro?le of‘ Acute Toxicity, Mice i.p. LDSO“ 
Name l X TDSO 2 X TD50 4 X TDSO (mg/kg) 
Com- (245 mg/kg) At 1 hr one of two (490 mg/kg) Both animals had (980 mg/kg) At 20 min, both 525.97 
pound animals exhibited decreased decreased motor activity, animals had decreased motor (473.77-564.48) 
10 motor activity, ataxia, rotorod ataxia, and rotorod toxicity at activity, ataxia, rotorod tox- 20.18 ' 
toxicity, and decreased respira- 10 min. In addition, decreased icity, muscle relaxation and 569.26 
tion. The remaining animal respiration was evident at 20 decreased respiration with (52098-64059) 
showed only ataxia. Both were min, and muscle relaxation with cyanosis. One animal had loss [14.55] 
normal at 24 hrs. cyanosis at 30 min with loss of of righting re?ex. The other 
righting re?ex at 2 hrs. One animal lost its righting re?ex 
animal regained its righting at 1 hr. One animal was dead 
re?ex at 4 hrs. Both animals at 4 hrs, the remaining animal 
were dead at 24 hrs. was dead at 24 hrs. 
Phenytoin (65 mg/kg) Increased motor (130 mg/kg) Mild ataxia, (260 mg/kg) Toxic manifesta- 178.34 
activity, slight ataxia, fre~ periods of sedation, spasms of tions identical to 2XTD50. At (15293-1954) 
quent grooming, nervous be- arching, rolling, straub tail, 1 hr, righting re?ex absent, 14.03 
havior, and straub tail, ptosis, and respiratory de- longer periods of sedation, 229.61 
animals were not toxic by the pression. Later, spasms re- and spasms reduced to head (21644-25910) 
rotorod test. duced and sedation increased. twisting and uncoordianted [15.89] 
At 24 hrs, toxicity present, movements; respiratory de~ 
other symptoms less pronounced. pression continued, mice dead 
at 24 hours. 
Pheno- (70 mg/kg) Ataxia with in- (140 mg/kg) Ataxia with in- (280 mg/kg) Ataxia with in- 135.45 
barbital creased motor activity followed creased motor activity followed creased motor activity follow- (11490-17742) 
by sedation and ptosis with by loss of righting re?ex, ed by loss of righting re?ex, 8.41 
one of two animals toxic by tremors, re?ex scratching, tremors, re?ex scratching, 264.70 
the rotorod test up to 4 hrs. ptosis, sedation and some ptosis, sedation, anesthesia (241.55-285.52) 
respiratory depression. Both with analgesia and respiratory [15.95] 
mice regained their righting depression. Both animals 
re?ex at 2 hrs and one of two became cold to touch and 
was still toxic by the rotorod cyanotic with increased res 
test at 8 hrs. piratory depression; death 
occurred at approximately 3 
and 6 hrs. 
Etho- (440 mg/kg) Uncoordinated (800 mg/kg) Uncoordinated (1760 mg/kg) Uncoordinated 850.61 
suximide motor activity, re?ex scratch- motor activity, re?ex scratch~ motor activity, respiratory (751.19—917.93) 
ing, respiratory depression, ing, loss of righting re?ex depression, hypnosis and [16.43] 
ataxia. at 4 mins but regained in 20 anesthesia followed at later 1752.23 
mins, hypnosis followed at time intervals by cyanosis (1607.02-1866.64) 
later time intervals by seda- and death at 24 hrs. [14.75] 
tion, ataxia, ptosis, vasodila 
tion and diarrhea. 
Valproate (400 mg/kg) Mild ataxia, with (800 mg/kg) Ataxia, with both 
one of two mice toxic by the 
rotorod test. Appeared 
normal at the end of 4 hrs. 
animals toxic by the rotorod 
test, normal respiration and 
some sedation. Both animals 
appeared normal at 4 hrs.) 
(1600 mg/kg) Both animals died. 
885.53 
(At 3XTD50 there was respira (82086-95704) 
tory depression, ptosis, hyp- 12.46] 
nosis but no analgesia. These 1104.62 
animals were dead at 4 hrs.) (1021.54-1253.66) 
[11.41] 
The LD50 (569.26 mg/kg) for Compound 10 was signif 
icantly higher than that for either phenytoin (229.61‘ 
mg/kg) or phenobarbital (264.70 mg/kg); however, it 
was signi?cantly lower than that for either valproate 
(1104.62 mg/kg) or ethosuximide (1752.23 mg/kg). 
The anticonvulsant activity and minimal neurotoxic 
dose (TD50) for Compound 10 as determined by Phase 
IV studies, Anticonvulsant Quanti?cation in Mice p.o., 
indicated that the TPE of Compound 10 after oral ad 
ministration was six hours by the rotorod test and one 
hour by the anticonvulsant tests. Except for Valproate, 
the four prototype agents exhibited TPE’s that were not 
signi?cantly different from those observed after the 
intraperitoneal administration of these agents. Valpro 
ate had a TPE of one to two hours after oral administra 
tion vs one-fourth hour after intraperitoneal administra 
tion. 
With respect to anticonvulsant activity as measured 
by the MES test, phenytoin was again the most potent 
(ED50: 9.04 mg/kg), whereas valproate was the least 
potent (ED50: 664.80 mg/kg). Compared to phenytoin, 
55 
60 
65 
phenobarbital was somewhat less potent by the MES 
test (ED50: 20.09 mg/kg). The test compound (Com 
pound 10) on the other hand, was 1/6 and 1/ 15 as po 
tent as phenobarbital and phenytoin, respectively, by 
the MES test with an ED50 of 131.67 mg/kg. When 
evaluated by the subcutaneous Metrazol threshold test 
after oral administration, phenobarbital was the most 
potent (ED50: 12.59 mg/kg) and Valproate was the least 
potent (ED50: 388.31 mg/kg). The other two com 
pounds (Compound 10 and ethosuximide) were essen 
tially equal in potency by the sc Met test with EDSO’s of 
135.67 and 192.21 mg/kg, respectively. 
By the oral route of administration in mice, Com~ 
pound 10, ethosuximide, and Valproate were essentially 
equitoxic (TD50’s: 729.08, 879,21, and 1264.39 mg/kg, 
respectively). Phenytoin and phenobarbital were the 
most toxic with quite similar TD50’s (86.71 and 96.78 
mg/kg. respectively). 
4,610,994 
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The PI. for Compound 10 is 5.54 by the MES test, 
whereas the P.I.’s for phenytoin, phenobabital, ethosux 
imide, and valproate are 9.59, 4.82, <0.44, and 1.90, 
respectively. The P.I. for Compound 10 by the sc Met 
test is 5.37, whereas those for phenytoin, phenobarbital, 
ethosuximide, and valproate are <0.29, 7.69, 4.56, and 
3.26, respectively. Thus, the RI. for Compound 10 of 
this invention by the MES test compares very favorably 
with the PI. for phenobarbital (5.54 and 4.82 respec 
tively), whereas the PI. for Compound 10 by the sc Met 
test (5.37) is lower than that for phenobarbital (7.69), 
but higher than that for either ethosuximide (4.56) or 
valproate (3.26). 
The results obtained in Phase V evaluation, Anti 
epileptic Drug Differentiation in Mice, indicated that 
the pro?le of anticonvulsant activity of Compound 10 is 
characterized by its effectiveness by the sc Met test and 
ineffectiveness by the so Bic, sc Pic, and so Strych tests. 
Thus, its pro?le of anticonvulsant action does not re 
semble that of any of the four prototype agents. Pheno 
barbital and valproate, on the other hand, were effec 
tive by all four anticonvulsant tests. However, it should 
be noted that valproate was effective against strychnine 
in nontoxic doses, whereas phenobarbital had to be 
given in toxic doses in order to protect against this 
chemical convulsant. Phenytoin, on the other hand, was 
ineffective against Metrazol, bicuculline, and picrotoxin 
and was only capable of providing protection in 50% of 
animals given strychnine. Ethosuximide was effective 
by the Sc Met, sc Bic, and sc Pic tests, and only pro 
tected a maximum of 62% of animals by the Sc Strych 
test. However, ethosuximide had to be given in toxic 
doses to protect against sc Bic seizures. 
In Phase VI studies, Anticonvulsant Quanti?cation in 
Rats p.o., it was found that the TPE for Compound 10 
in this species after oral administration was two hours 
by the toxicity test and four hours by the MES and so 
Met tests. The TPE of the other four compounds 
ranged from one-half hour for valproate to ?ve hours 
for phenobarbital. 
With respect to anticonvulsant activity it may be seen 
that after oral administration in rats, phenobarbital was 
the most potent by the MES test (ED50: 9.14 mg/kg), 
20 
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whereas valproate was the least potent (ED50: 489.54 
mg/kg). The EDSO’s of phenytoin and Compound 10 
by this test were 29.82 and 49.89 mg/kg, respectively. 
When compared on the basis of the sc Met test, pheno 
barbital was the most potent (ED50: 11.55 mg/kg) and 
Compound 10 was the least potent (ED50: 329.18 
mg/kg). Ethosuximide and valproate were less potent 
than phenobarbital by this test with ED50’s of 53.97 and 
179.62 mg/kg, respectively. 
With regard to neurotoxicity, Compound 10 and 
phenobarbital were essentially equitoxic (44.48 and 
61.09 mg/kg, respectively) and ethosuximide and phe 
nytoin the least toxic (TD50’s: 1012.31 and >3000 
mg/kg, respectively). Valproate was intermediate in 
toxicity with a TD5O of 280.26 mg/kg. 
The P.I.’s by the MES test vary from 0.57 for valpro 
ate, < 0.84 for ethosuximide, and 0.89 for Compound 10 
to >100 for phenytoin. The PI. for phenobarbital is 
6.68. The P.I.’s for compounds active by the sc Met test 
range from 0.14 and 1.56 for Compound 10 and valpro 
ate, respectively, to 18.76 for ethosuximide; the PI for 
phenobarbital by this test is 5.29. Phenytoin is ineffec 
tive by this test. 
Phase VII studies of Compound 10 included ?ve-day 
LD3, ?ve-day tolerance studies, and effect of chronic 
administration on the liver microsomal enzyme system. 
The ?ve-day oral LD3 of Compound 10 is <300 mg/kg 
in male rats and >300 mg/kg in female rats. The ?ve 
day tolerance studies in rats indicate that signi?cant 
tolerance occurs within this period of time (MES test: 1 
of 8 protected in chronic-treated group; 6 of 8 protected 
in acute [single dose] control group; hexobarbital sleep 
time, 15.0i2.0 and 16.3: 1.2 min in chronic-treated and 
acute control group, respectively. This interpretation is 
further supported by the fact that there were signi?cant 
increases in cytochrome P-450 (09881-0096 vs 
0720:0054 n moles/mg, p-nitroanisole O-demethylase 
(06401-0098 11 moles/mg/min in treated vs 
0.261 i0.035 in controls), and cytochrome C reductase 
(2195124 11 moles/mg/min in treated vs 157111 in con 
trols) of chronically treated rats as compared to the 
acute (single dose) control group. 
TABLE 5 
QUANTITATIVE TOXICITY PROFILE OF 
INTRAPERITONEALLY ADMINISTERED COMPOUND 10 
AND SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE, 
Time Rotorod 
ADD No. of Test TD5O EDSO (mg/kg) and PI 
Substance (hrs) (mg/kg) MES sc Met Bicuculline Picrotoxin Strychnine 
Compound 10 1, 1, 1 244.51 65.76 26.95 NO [116L125 NO [E2] 1 pro 
(221.82- (51.82-83.19) (9.89-5508) protection protection tected at 250; no 
275.17) [5.43] [1.21] up to 300 up to 300 protection at 300 
[13.86] 
Phenytoin 2, 2 65.46 9.50 @ No No No EJE Maximum@ 
(52.49-72.11) (8.13-10.44) Protection Protection Protection 50% protection 
[15.23] [13.66] up to 300 up to 100 up to 100 at 55-100 
Phenobarbital 3, 1, 1 69.01 21.78 13.17 37.72 27.51 95.30 
(62.84-72.89) (14.99-25.52) (5.87-1593) (26.49-47.39) (20.88-34.82) (91.31-99.52) 
[24.67] [14.98] [5.93] [4.07] [4.79] [18.51] 
Ethosuximide 1, 3, 1 440.83 No 130.35 459.01 242.69 [E] MaximumE: 
(383.09- protection (11099-15045) (34992-63513) (22784-25522) 62% protection 
485.34) up to 1000 [10.06] [3.21] [26.43] at 250-1000 
[12.37] 
4,610,994 
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TABLE S-continued 
QUANTITATIVE TOXICITY PROFILE OF 
INTRAPERITONEALLY ADMINISTERED COMPOUND 10 
AND SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE. 
Time Rotorod - 
ADD No. of Test TDSO EDSO (mg/kg) and P1 
Substance (hrs) (mg/kg) MES 60 Met Bicuculline Picrotoxin Strychnine 
Valproate I, A, 4 425.84 271.66 148.59 359.95 387.21 IE 292.96 
(368.91- (246.97-337.89) (12264-17702) (29407-43854) (341.37-44438) (261.I2-3Z3.43) 
450.40) [12.83] [11.87] [7.51] [8.35] [11.80] 
[20.84] 
( ) 95% Con?dence interval 
[ ] Slope, regression line 
' Protective Index (P.1.) = TD50/ED5O 
TABLE 6 
PROFILE OF ANTICONVULSANT ACTIVITY 
OF ORALLY ADMINISTERED COMPOUND 10 AND SOME 
PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE AND RATS 
Time of Test TDSO MES-EDSO sc Met-EDSO 
Add No. (hrs) (mg/kg) (mg/kg) (mg/kg) 
Substance Mice Rats Mice Rats Mice Rats Mice Rats 
44.48 
Compound 10 6, 1, 1 2, 4, 4 729.08 (32.784261) 131.67 49.89 I 0.89’ I 13567 I 5.37* I 329.18 I 0.14‘ I 
(49247-100917) [421] (10890-16574) (31.15-73.15) (71.74-210.07) (83.41—5690.66) 
[3.03] [6.04] [2.93] [2.16] [0.89] 
Phenytoin 2, 2, 2 -, 4, 4 86.71 No ataxia up 9.04 29.82 I < 100 I No I<O.29 I No 
(80.39-96.09) to 3000 (739-1062) (21.92-38.91) Protection Protection 
[13.01] [6.28] [2.82] up to 300 up to 800 
Phenobarbital 2, 2, 2 3, 5, 5 96.78 61.09 20.09 [E] 9.14 12.59 11.55 
(7988-11500) (43.72-95.85) (14.73-31.58) (7.58-1 1.86) (7.99—] 1.86) (7.75—15.00) 
[8.51] [3.00] [5.20] [4.12] [4.12] [4.08] 
Ethosuximide 1, 8, 3 2, 2, 2 879.21 1012.31 No @I No |<0.84| 192.21 I 3.26 | 53.97 I18.76 I 
(83949-93351) (901.66-1109.3l) protection protection (l58.S9-438.61) (45.57-60.85) 
[305°] [15.33] up to 2000 up to 1200 [8.12] [9.05] 
Valproate 2, 1, 1 lY g, 3 1264.39 280.26 664.80 489.54 388.31 179.62 
(800-2250) (191.32-35276) (19132-35276) (351.14—728.37) (348.87-438.61) (14673-21035) 
[4.80] [4.63] [4.63] [2.90] [8.12] [8.62] 
( ) 95% Con?dence intervaI 
[ ] Slope. regression line 
' Protective Index (P.I.) = TD50/ED50 
TABLE 7 
QUANTITATIVE TOXICITY PROFILE OF 
INTRAPERITONEALLY ADMINISTERED COMPOUND 10 
AND SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE. 
Time 
ADD N0. of Test DOSE 50 (mg/kg) 
Substance (hrs) Lethality Righting Re?ex Rotorod 
Compound 10 24, 6,1 569.24 525.98 [E 244.51 IE] 
(52098-65059) (47377-56448) (22282-27517) 
[14.55] [20.18] [13.86] 
Phenytoin 24, 12,2 229.61 178.34 65.46 IE 
(21644-25910) (15293-19545) (52.46-72.11 
[15.89] [14.03] [15.23] 
Phenobarbital 241,] 264.70 135.45 69.01 [135 
(24155-28552) (11490-17742) (62.84-72.89) 
[15.95] [8.41] [24.67] 
Ethosuximide 24.3.3 1752.23 850.61 44.83 
(1607.02—1866.64) (75119-91793) (38309-48534) 
[14.75] [16.43] [18.37] 
4,610,994 
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QUANTITATIVE TOXICITY PROFILE OF 
INTRAPERITONEALLY ADMINISTERED COMPOUND 10 
AND SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE. 
Time 
ADD No. of Test DOSE 50 (mg/kg) 
Substance (hrs) Lethality Righting Re?ex Rotorod 
Valproate 24, I, 1 1104.62 885.53 425.84 
(1021.54—l253.66) (82086-94704) (36831-45040) 
[11.41] [12.46] [20.84] 
( ) 95% Con?dence interval 
[ ] Slope. regression line 
' Protective Index {P.I.) = TDSO/EDSO 
The pro?les of anticonvulsant activity of Compound 10 
and the four prototype agents after intraperitoneal ad 
ministration in mice and oral administration in mice and 
rats are summarized in Tables 5 and 6, respectively. It is 
seen from Table 5 that, in terms of the pro?le of anti 
convulsant activity, Compound 10 does not resemble 
any of the four prototype agents. Unlike phenobarbital 
and valproate, Compound 10 is ineffective in doses up 
to 300 mg/kg after i.p. administration in mice by the sc 
Bic, sc Pic, and so Strych tests, whereas phenobarbital 
and valproate are effective by these tests. In terms of 
rotorod toxicity, the Compound 10 is approximately 
20 
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respectively. Thus the ratios between either the minimal 
toxic dose and the 24-hour lethal dose or the loss of 
righting re?ex does and the 24-hour lethal dose for 
Compound 10 are lower than those for any of the four 
candidate substances; hence, the margin between the 
minimal toxic dose and the 24-hour lethal dose in mice 
is unusually narrow. 
The selectivity exhibited by Compound 10 and the 
four prototype agents as indicated by the slopes of the 
regression lines derived from the MES, sc Met, rotorod 
loss of righting re?ex, and 24-hour lethality tests (mice, 
i.p.) is summarized below: 
Correlation Between the Slopes of the Regression Lines 
for Compound 10 and the Prototype Agents 
Right. Deaths 
MES Sc Met Rotorod Re?ex 24 hours 
Compound Compound Compound Compound Compound 
Prototype l0 l0 10 10 1O 
Phenytoin ‘ " X ‘ X 
Phenobarbital ‘ ' " ‘ X 
Ethosuximide ‘ ‘ * X 
Valproate ‘ ‘ * “ X 
X Correlates with indicated prototype to a certain extent 
‘Does not correlate well with prototype agent. 
twice as toxic as either ethosuximide or valproate in this 
species. It may be seen from Table 6 that after oral 
administration, Compound 10 is approximately 16 times 
more neurotoxic in rats than it is in mice; likewise, Com 
pound 10 is about 2% times more potent by the sc Met 
test in mice than in rats. It should be noted that phenyt 
oin administered orally in higher doses is absorbed only 
to a limited extent from the gastrointestinal tract of rats. 
Consequently, no minimal neurotoxicity was observed 
in this species even in doses up to 3000 mg/kg (see 
Table 6). 
The quantitative toxicity pro?les after intraperitone 
ally administering Compound 10 and the four prototype 
agents in mice are summarized in Table 7. It may be 
seen that the times of peak toxicity for phenytoin by the 
rotorod and righting re?ex tests are 2 and 12 hours, 
respectively, whereas the TPE for Compound 10 by the 
righting re?ex test is 6 hours. The TPE for the other 
three prototype agents by the rotorod and righting 
re?ex tests range from one-fourth to one hour. This 
table also shows that the LDSO/HDSO and 
LD50/TD50 ratios for Compound 10 are 1.08 and 2.33, 
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It may be seen from the above summary that in terms of 
selectivity of effect as indicated by the slope of the 
regression lines, Compound 10 resembles phenytoin by 
the rotorod test; ethosuximide by the righting re?ex 
test; and all the prototype agents by the 24-hour lethal 
ity test. In marked contrast, Compound 10 does not 
resemble any of the prototype agents by either the MES 
or sc Met tests. The reason Compound 10 does not 
resemble the prototype agents by the MES test is due to 
flatter slopes of the regression lines (5.43 for Compound 
10 vs 13.66, 14.98, and 12.83 for phenytoin, phenobarbi 
tal, and valproate, respectively); similarly, Compound 
10 has a much ?atter slope by the sc Met test (1.21 for 
Compound 10 vs 5.93, 10.06, and 11.84 for phenobarbi 
tal, ethosuximide and valproate, respectively). 
Since all protective indices (P.I.‘s) are based on the 
assumption that the slope of the regression lines (toxic 
ity and activity) are parallel, it is important to note the 
effect of slope on the’ safety ration (SR=TD3/ED97) 
for Compound 10, phenobarbital, and valproate. The 
safety ratios of these substances are summarized below. 
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Safety Ratios‘ (TD3/ED97) of Compound 10, 
Phenobarbital, and Valproate 
Substance and Test 
Species & Compound 10 Phenobarbital Valproate 
Parameter Route Admin. MES sc Met MES sc Met MES sc Met 
TD3 Mice, i.p. 175 175 57 57 345 345 
ED97 " 145 900 29 27 380 218 
Ratio 1.2 0.2 2.3 2.5 0.9 1.6 
TD3 Mice, oral 173 173 58 58 500 500 
ED97 " 275 980 46 38 840 680 
Ratio 0.6 0.2 1.3 1.5 0.6 0.7 
TD3 Rats, oral l6 l6 l4 14 115 115 
ED97 " 215 > 10000 26 34 1800 188 
Ratio 0.07 0.002 0.5 0.4 0.1 0.6 
‘Ratios less than 1 indicate that 97% protection is obtained only with some minimal neurotoxicity. 
The above summary indicates that after intraperito 
neal administration of nontoxic doses, the test substance 
(Compound 10) will protect 97% of mice subjected to 
the MES test, whereas toxic doses are required to pro 
vide this same level of protection by the sc Met test. 
After oral administration of the test substance in mice 
and rats, toxic doses are required to protect 97% of 
animals by either the MES or so Met test. Moreover, 
the candidate substance (Compound 10) and the two 
prototype agents used for comparison of the safety 
ratios do not provide 97% protection by the MES and 
sc Met tests in nontoxic doses after oral administration 
in rats. 
For a candidate drug to be useful in man, it should be 
adequately absorbed after oral administration. The ex 
tent of oral absorption can be determined from the ratio 
of the oral ED50/i.p. ED50 for a desired pharmaco 
logic activity and should be equal to or less than 4 for 
adequate absorption. The oral TD50/i.p. TD50 and oral 
ED50/i.p. ED50 ratios for Compound 10 in mice are 
2.98, 2.00, and 5.03 by the rotorod MES, and se Met 
tests, respectively. This suggests that Compound 10 is 
adequately absorbed in mice after oral administration. 
Chronic studies indicate that Compound 10 is more 
toxic in male than in female rats. Thus, the estimated 
?ve-day LD3 for Compound 10 is <300 mg/kg in male 
rats and >300 but <1000 mg/kg in female rats. The 
?ve-day chronic studies also demonstrate that signi? 
cant toleance to the anticonvulsant effects of Com 
pound 10 develops in rats within this short period of 
time. This interpretation is con?rmed, not only by the 
marked difference in response to the MES test (single 
dose of 50 mg/kg, 6 of 8 rats protected; ?ve daily doses 
of 50 mg/kg, 1 of 8 protected), but also by the signi? 
cant increase observed in liver cytochrome P-450 
(37%), p-nitroanisole O-demethylase (145%), and cyto 
chrome C reductase (40%). 
For a candidate antiepileptic substance to be useful in 
the treatment of seizure disorders, its experimental pro 
?le of action should compare favorably with that of 
clinically useful antiepileptic drugs. Such a comparison 
should include not only the anticonvulsant efficacy 
(ED50), but also the selectivity of toxic and anticonvul 
sant effects (slope of the dose-effect regression line), 
toxicity (LDSO, HDSO, and TD50), protective indices 
(TD50/ED50), safety ratios (TD3/ED97), absorption 
characteristics (oral ED50/i.p. ED50 and oral 
TD50/i.p. TD50) and the margin of safety (single dose 
?ve-day LDSO/EDSO). An analysis of the data for 
Compound 10, phenobarbital, ethosuximide and valpro 
ate shows the relative merits and the disadvantages of 
Compound 10. The merits of the candidate substance 
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Compound 10 are the favorable safety ratios, 
TD3/ED97 by the MES test and 24-hour LD50/ED50 
by the sc Met test. The disadvantages are related to a 
lack of selectivity (?at regression line) by the MES test, 
the unfavorable ratio (TD3/ED97) by the sc Met test, 
and the toxicity ratios (24-hour LDSO/HDSO and 24 
hour LDSO/T D50). 
The invention has been described herein with refer 
ence to certain preferred embodiments. However, as 
obvious variations thereon will become apparent to 
those skilled in the art, the invention is not to be consid 
ered as limited thereto. 
I claim: 
1. A compound of the following formula: 
R2 
wherein R1 is 4-pyridyl, or 3-pyridyl and R1 is m 
methyl, m- or p-?uoro, m-chloro, m- or p-bromo, m- or 
p-tri?uoromethyl, 3,4-dichloro, or 3,5-dichloro. 
2. A compound according to claim 1 wherein R1 is 
4-pyridyl and R2 is meta-chloro. 
3. A compound according to claim 1 wherein R1 is 
4~pyridyl and R2 is 3,4-dichloro. 
4. A compound according to claim 1 wherein R1 is 
4-pyridyl and R2 is 3,5-dichloro. 
5. A compound according to claim 1 wherein R1 is 
3-pyridyl and R2 is para-chloro. 
6. A compound according to claim 1 wherein R1 is 
3-pyridyl and R2 is para-bromo. 
7. A compound according to claim 1 wherein R1 is 
3-pyridyl and R2 is para-?uoro. 
8. A compound according to claim 1 wherein R1 is 
3-pyridyl and R2 is 3,4-dichloro. 
9. A compound according to claim 1 wherein R1 is 
4-pyridyl and R2 is meta-fluoroi 
10. A compound according to claim 1 wherein R1 is 
4-pyridyl and R2 is meta-bromo. 
11. A compound according to claim 1 wherein R1 is 
4-pyridyl and R2 is meta-methyl. 
12. A compound according to claim 1 wherein R1 is 
4-pyridyl and R2 is meta-trifluoromethyl. 
13. A compound according to claim 1 wherein R1 is 
3-pyridyl and R2 is para-tri?uoromethyl. 
14. A compound according to claim 1 wherein R1 is 
4-pyridyl and R2 is para-fluoro. 
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15. An anticonvulsant composition comprising an 
effective amount of a compound selected from the 
group consisting of those of the formulae: 
wherein R1 is 4-pyridyl, 3-pyridyl, or 2-pyridyl and R2 
is hydrogen, m- or p-methyl, p-methoxy, m- or p~ 
chloro, m- or p-bromo, m- or p-fluoro, m- or p-tri 
fluoromethyl, 3,4-dichloro or 3,5-dichloro and a phar 
maceutically acceptable carrier or adjuvent. 
16. A composition according to claim 1 wherein R1 is 
4-pyridyl and R2 is hydrogen. 
17. A composition according to claim 1 wherein R1 is 
4-pyridyl and R2 is para-?uoro. 
18. A composition according to claim 1 wherein R1 is 
4-pyridyl and R2 is para-methyl. 
19. A composition according to claim 1 wherein R1 is 
4-pyridyl and R2 is para-methoxy. 
20. A composition according to claim 1 wherein R1 is 
4-pyridyl and R2 is meta-chloro. 
21. A composition according to claim 1 wherein R1 is 
4-pyridyl and R2 is 3,4-dichloro. 
22. A composition according to claim 1 wherein R1 is 
4-pyridyl and R2 is 3,5-dichloro. I 
23. A composition according to claim 1 wherein R1 is 
3-pyridyl and R2 is para-chloro. 
24. A composition according to claim 1 wherein R1 is 
3-pyridyl and R2 is para-bromo. 
25. A composition according to claim 1 wherein R1 is 
3-pyridyl and R2 is para-?uoro. 
26. A composition according to claim 1 wherein R1 is 
3-pyridyl and R2 is 3,4-dichloro. 
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27. A composition according to claim 1 wherein R1 is 
Z-pyridyl and R2 is para-chloro. 
28. A composition according to claim 1 wherein R1 is 
4-pyridyl and R1 is meta-fluoro. 
29. A composition according to claim 1 wherein R1 is 
4-pyridyl and R2 is meta-bromo. 
30. A composition according to claim 1 wherein R1 is 
4-pyridyl and R2 is meta-methyl. 
31. A composition according to claim 1 wherein R1 is 
4-pyridyl and R2 is meta-tri?uoromethyl. 
32. A composition according to claim 1 wherein R1 is 
3-pyridyl and R2 is para-trifluoromethyl. 
33. A composition according to claim 1 wherein a 
sufficient amount of the effective ingredient is con 
tained in said composition to provide a dosage amount 
ranging from about 25 mg/kg to 300 mg/kg. 
34. A method for the treatment of convulsive disor 
ders in mammals which comprises administration 
thereto of an effective dosage amount of a composition 
of claim 23. 
35. A method for the treatment of convulsive disor 
ders in mammals which comprises administration 
thereto of an effective dosage amount of an anticonvul 
sant composition comprising an effective amount of a 
compound selected from the group consisting of those 
of the formulae: 
wherein R1 is 4-pyridyl, 3-py‘ridyl, Z-pyridyl or phenyl 
and R2 is hydrogen, m- or p-methyl, p-methoxy, m- or 
p-chloro, m- or p-bromo, m- or p-fluoro, m- or p-tri 
?uoromethyl, 3,4-dichloro or 3,5-dichloro and a phar 
maceutically acceptable carrier or adjuvent. 
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